Rheos Medicines, Inc.
38 Sidney Street, 2nd Floor
Cambridge
MA
02138
United States
Tel: (857) 777-4242
About Rheos Medicines, Inc.
We are leading the way in the emerging field of immunometabolism to develop novel, precision medicines to treat patients with immune-mediated diseases.
Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Our approach targets the underlying cellular metabolism of immune cells in order to redirect the fate and function of specific cell types to treat immune-mediated diseases. By simultaneously identifying new drug targets and characterizing biomarkers of disease, we are bringing precision to treatment of immune-mediated diseases. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of the heterogeneity of immune-mediated diseases, and an experienced leadership team.
Founded by Third Rock Ventures, Rheos is dedicated to changing how immune-mediated diseases are treated.
10 articles with Rheos Medicines, Inc.
-
Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer
8/9/2021
Brings leadership experience from Agios Pharmaceuticals and Novartis Vaccines with strategy and operations expertise across many stages of product development and company growth
-
Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors
7/12/2021
Rheos Medicines today announced the appointment of John Davis, Jr., M.D., M.P.H., M.S. to its board of directors.
-
Rheos Medicines to Present at Jefferies Virtual Healthcare Conference
5/27/2021
Rheos Medicines, a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine engine (MetPM) announced that Barbara S. Fox , Ph.D., Chief Executive Officer of Rheos Medicines, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12:30 p.m.
-
Rheos Medicines Appoints Dania Rabah, Ph.D., as Chief Scientific Officer
10/21/2020
Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe immune-mediated diseases, announced today that Dania Rabah, Ph.D., has been hired as the company’s Chief Scientific Officer.
-
Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit
9/28/2020
Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe immune-mediated diseases, will participate in the upcoming Immunology and Inflammation Virtual Summit hosted by Stifel. Dr. Edward Driggers, Rheos’s Chief Technology Officer, will participate in a panel discussion entitled “The Key To Unlocking Immune Cell Function” at 2:00
-
Rheos Medicines to Present at the Cowen and Company 40th Annual Health Care Conference
2/18/2020
Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that Barbara S. Fox, Ph.D., the Company’s Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference
-
Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism
12/19/2019
Rheos Medicines (Rheos), a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that it has entered into a worldwide exclusive collaboration, option and license agreement with Roche to discover, develop and commercialize novel therapeutics in the field of immunometabolism.
-
Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of Immunometabolism to Discover and Develop Novel Medicines
12/12/2019
The new field of immunometabolism is the study of how metabolic pathways control immune cell differentiation and function
-
Rheos Medicines Appoints Barbara S. Fox as Chief Executive Officer
10/21/2019
Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, announced the appointment of industry veteran Barbara S. Fox, Ph.D., to Chief Executive Officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.